Combinatorial Drug Testing in 3D Microtumors Derived from GBM Patient-Derived Xenografts Reveals Cytotoxic Synergy in
Ashley N Gilbert1, Joshua C Anderson2, Christine W Duarte3
1The University of Alabama at Birmingham, Department of Biomedical Engineering, Birmingham, AL, 35249, USA.
Abstract:
Glioblastoma multiforme (GBM), the most common form of primary malignant brain cancer in adults, is a devastating disease for which effective treatment has remained elusive for over 75 years. One reason for the minimal progress during this time is the lack of accurate preclinical models to represent the patient's tumor's in vivo environment, causing a disconnect in drug therapy effectiveness between the laboratory and clinic. While patient-derived xenografts (PDX's or xenolines) are excellent human tumor representations, they are not amenable to high throughput testing. Therefore, we developed a miniaturized xenoline system (microtumors) for drug testing. Nineteen GBM xenolines were profiled for global kinase (kinomic) activity revealing actionable kinase targets associated with intracranial tumor growth rate. Kinase inhibitors for these targets (WP1066, selumetinib, crizotinib, and cediranib) were selected for single and combination therapy using a fully human-derived three-dimensional (3D) microtumor model of GBM xenoline cells embedded in HuBiogel for subsequent molecular and phenotype assays. GBM microtumors closely resembled orthotopically-implanted tumors based on immunohistochemical analysis and displayed kinomic and morphological diversity. Drug response testing could be reproducibly performed in a 96-well format identifying several synergistic combinations. Our findings indicate that 3D microtumors can provide a suitable high-throughput model for combination drug testing.
Insights
Researchers developed a novel 3D microtumor model for glioblastoma (GBM) drug testing. This high-throughput system accurately predicts synergistic drug combinations, overcoming limitations of traditional preclinical models.
Area of Science:
- Oncology
- Biotechnology
- Drug Discovery
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain cancer with limited treatment options.
- Existing preclinical models lack accuracy, hindering drug development and clinical translation.
- Patient-derived xenografts (PDXs) are valuable but not suitable for high-throughput screening.
Purpose of the Study:
- To develop a miniaturized, high-throughput preclinical model for glioblastoma drug testing.
- To identify actionable kinase targets and evaluate drug efficacy in a 3D microtumor system.
- To assess the suitability of 3D microtumors for reproducible drug response and combination therapy screening.
Main Methods:
- Developed a 3D microtumor model using GBM xenoline cells embedded in HuBiogel.
- Profiled kinomic activity of 19 GBM xenolines to identify therapeutic targets.
- Tested single and combination therapies with kinase inhibitors (WP1066, selumetinib, crizotinib, cediranib) in the 96-well microtumor format.
Main Results:
- GBM microtumors accurately mimicked orthotopic tumors via immunohistochemical analysis.
- The model demonstrated kinomic and morphological diversity across different GBM xenolines.
- Reproducible drug response testing identified several synergistic drug combinations for GBM treatment.
Conclusions:
- The 3D microtumor system offers a viable, high-throughput platform for preclinical glioblastoma drug screening.
- This model facilitates the identification of effective combination therapies for GBM.
- The findings bridge the gap between laboratory research and clinical drug efficacy for GBM.
Related Concept Videos
Combinatorial Gene Control
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
Measurement: Derived Units
Higher Derivatives
Derivatives
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Derivative as a Function


